
PRODUCT INFORMATION

FT895

Item No. 45835

CAS Registry No.:	2225728-57-2
Formal Name:	2,3-dihydro-N-hydroxy-1,1-dimethyl-2-[5-(trifluoromethyl)-2-pyrazinyl]-1H-isoindole-4-carboxamide
MF:	$C_{16}H_{15}F_3N_4O_2$
FW:	352.3
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

FT895 is supplied as a solid. A stock solution may be made by dissolving the FT895 in the solvent of choice, which should be purged with an inert gas. FT895 is slightly soluble (0.1-1 mg/ml) in acetonitrile and DMSO.

Description

FT895 is an inhibitor of histone deacetylase 11 (HDAC11; IC_{50} = 3 nM).[1] It is selective for HDAC11 over HDAC1-7 (IC_{50}s = >10,000 nM for all), HDAC8 (IC_{50} = 5,600 nM), and HDAC9-10 (IC_{50}s = >10,000 nM for both). FT895 induces cytotoxicity in Hs 53.T neurofibroma and S462.TY malignant peripheral nerve sheath tumor (MPNST) cells (IC_{50}s = 13.12 and 6.76 µM, respectively).[2] It increases the levels of reactive oxygen species (ROS) in S462.TY cells at 10 µM and reduces mitochondrial basal and maximal respiration at 10 and 20 µM in the same cells.[3] FT895 (0.5 mg/kg) enhances the reduction in tumor size induced by cordycepin (Item No. 14426) in an S462.TY mouse xenograft model.[2] It also increases the production of nitric oxide (NO) in human monocyte-derived macrophages infected with heat-killed *C. albicans*. FT895 (50 mg/kg) reduces renal inflammation and fungal burden and increases survival in a mouse model of *C. albicans* infection.[4]

References

1. Martin, M.W., Lee, J.Y., Lancia, D.R., Jr., *et al.* Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. *Bioorg. Med. Chem. Lett.* **28(12)**, 2143-2147 (2018).
2. Huang, P.Y., Shih, I.A., Liao, Y.C., *et al.* A novel HDAC11 inhibitor potentiates the tumoricidal effects of cordycepin against malignant peripheral nerve sheath tumor through the Hippo signaling pathway. *Am. J. Cancer Res.* **12(2)**, 873-892 (2022).
3. Huang, P.Y., Shih, I.A., Liao, Y.C., *et al.* FT895 Impairs mitochondrial function in malignant peripheral nerve sheath tumor cells. *Int. J. Mol. Sci.* **25(1)**, 277 (2023).
4. Wu, H., Yin, X., Zhao, X., *et al.* HDAC11 negatively regulates antifungal immunity by inhibiting *Nos2* expression via binding with transcriptional repressor STAT3. *Redox Biol.* **56**, 102461 (2022).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/31/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM